1. Home
  2. DH vs IMMP Comparison

DH vs IMMP Comparison

Compare DH & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Definitive Healthcare Corp.

DH

Definitive Healthcare Corp.

N/A

Current Price

$1.12

Market Cap

283.1M

Sector

Technology

ML Signal

N/A

Logo Immutep Limited

IMMP

Immutep Limited

N/A

Current Price

$0.36

Market Cap

58.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DH
IMMP
Founded
2011
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
283.1M
58.2M
IPO Year
2021
2012

Fundamental Metrics

Financial Performance
Metric
DH
IMMP
Price
$1.12
$0.36
Analyst Decision
Hold
Hold
Analyst Count
5
3
Target Price
$3.43
$5.50
AVG Volume (30 Days)
392.1K
3.1M
Earning Date
05-07-2026
02-22-2026
Dividend Yield
N/A
N/A
EPS Growth
63.28
N/A
EPS
N/A
N/A
Revenue
$241,521,000.00
N/A
Revenue This Year
N/A
$382.75
Revenue Next Year
$0.30
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.97
$0.38
52 Week High
$4.70
$3.53

Technical Indicators

Market Signals
Indicator
DH
IMMP
Relative Strength Index (RSI) 35.39 13.31
Support Level $1.07 N/A
Resistance Level $1.29 $1.90
Average True Range (ATR) 0.09 0.09
MACD 0.03 -0.19
Stochastic Oscillator 43.68 0.58

Price Performance

Historical Comparison
DH
IMMP

About DH Definitive Healthcare Corp.

Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: